Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomas.

Nerve growth factor (NGF) administration to athymic mice with transplanted human bromocriptine-resistant prolactinoma, results in the expression of dopamine D-2 receptors in the tumour and restores sensitivity to subsequent treatment with bromocriptine, which then produces normalisation of plasma pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Missale, C., Losa, M., Boroni, F., Giovanelli, M., Balsari, A., Spano, P. F.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1995
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2034102/
https://www.ncbi.nlm.nih.gov/pubmed/8519650
_version_ 1782136983002284032
author Missale, C.
Losa, M.
Boroni, F.
Giovanelli, M.
Balsari, A.
Spano, P. F.
author_facet Missale, C.
Losa, M.
Boroni, F.
Giovanelli, M.
Balsari, A.
Spano, P. F.
author_sort Missale, C.
collection PubMed
description Nerve growth factor (NGF) administration to athymic mice with transplanted human bromocriptine-resistant prolactinoma, results in the expression of dopamine D-2 receptors in the tumour and restores sensitivity to subsequent treatment with bromocriptine, which then produces normalisation of plasma prolactin and tumour regression. Sequential administration of NGF and bromocriptine thus may be a promising therapy for patients refractory to bromocriptine. IMAGES:
format Text
id pubmed-2034102
institution National Center for Biotechnology Information
language English
publishDate 1995
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20341022009-09-10 Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomas. Missale, C. Losa, M. Boroni, F. Giovanelli, M. Balsari, A. Spano, P. F. Br J Cancer Research Article Nerve growth factor (NGF) administration to athymic mice with transplanted human bromocriptine-resistant prolactinoma, results in the expression of dopamine D-2 receptors in the tumour and restores sensitivity to subsequent treatment with bromocriptine, which then produces normalisation of plasma prolactin and tumour regression. Sequential administration of NGF and bromocriptine thus may be a promising therapy for patients refractory to bromocriptine. IMAGES: Nature Publishing Group 1995-12 /pmc/articles/PMC2034102/ /pubmed/8519650 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Missale, C.
Losa, M.
Boroni, F.
Giovanelli, M.
Balsari, A.
Spano, P. F.
Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomas.
title Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomas.
title_full Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomas.
title_fullStr Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomas.
title_full_unstemmed Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomas.
title_short Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomas.
title_sort nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomas.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2034102/
https://www.ncbi.nlm.nih.gov/pubmed/8519650
work_keys_str_mv AT missalec nervegrowthfactorandbromocriptineasequentialtherapyforhumanbromocriptineresistantprolactinomas
AT losam nervegrowthfactorandbromocriptineasequentialtherapyforhumanbromocriptineresistantprolactinomas
AT boronif nervegrowthfactorandbromocriptineasequentialtherapyforhumanbromocriptineresistantprolactinomas
AT giovanellim nervegrowthfactorandbromocriptineasequentialtherapyforhumanbromocriptineresistantprolactinomas
AT balsaria nervegrowthfactorandbromocriptineasequentialtherapyforhumanbromocriptineresistantprolactinomas
AT spanopf nervegrowthfactorandbromocriptineasequentialtherapyforhumanbromocriptineresistantprolactinomas

Ejemplares similares